Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. by Gentiluomo, Manuel et al.
1
Vol.:(0123456789)
Scientific Reports |         (2021) 11:7570  | https://doi.org/10.1038/s41598-021-87130-0
www.nature.com/scientificreports
Lack of association 
of CD44‑rs353630 
and CHI3L2‑rs684559 
with pancreatic ductal 
adenocarcinoma survival
Manuel Gentiluomo1, Chiara Corradi1, Giuseppe Vanella2,3, Astrid Z. Johansen4, 
Oliver Strobel5, Andrea Szentesi6,7, Anna Caterina Milanetto8, Péter Hegyi6,7, 
Juozas Kupcinskas9, Francesca Tavano10, John P. Neoptolemos5, Dania Bozzato11, 
Thilo Hackert5, Raffaele Pezzilli12, Julia S. Johansen4,13, Eithne Costello14, 
Beatrice Mohelnikova‑Duchonova15, Casper H. J. van Eijck16, Renata Talar‑Wojnarowska17, 
Carsten Palnæs Hansen18, Erika Darvasi7, Inna M. Chen4, Giulia Martina Cavestro19, 
Pavel Soucek20, Liliana Piredda21, Pavel Vodicka22, Maria Gazouli23, 
Paolo Giorgio Arcidiacono2, Federico Canzian24, Daniele Campa1,25* & Gabriele Capurso2,3,25 
Although pancreatic ductal adenocarcinoma (PDAC) survival is poor, there are differences in patients’ 
response to the treatments. Detection of predictive biomarkers explaining these differences is of the 
utmost importance. In a recent study two genetic markers (CD44‑rs353630 and CHI3L2‑rs684559) 
were reported to be associated with survival after PDAC resection. We attempted to replicate the 
associations in 1856 PDAC patients (685 resected with stage I/II) from the PANcreatic Disease 
ReseArch (PANDoRA) consortium. We also analysed the combined effect of the two genotypes 
in order to compare our results with what was previously reported. Additional stratified analyses 
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considering TNM stage of the disease and whether the patients received surgery were also performed. 
We observed no statistically significant associations, except for the heterozygous carriers of 
CD44‑rs353630, who were associated with worse OS (HR = 5.01; 95% CI 1.58–15.88; p = 0.006) among 
patients with stage I disease. This association is in the opposite direction of those reported previously, 
suggesting that data obtained in such small subgroups are hardly replicable and should be considered 
cautiously. The two polymorphisms combined did not show any statistically significant association. 
Our results suggest that the effect of CD44‑rs353630 and CHI3L2‑rs684559 cannot be generalized to 
all PDAC patients.
Pancreatic ductal adenocarcinoma (PDAC) is a lethal tumour type, with an increasing incidence over the past 
decades and a five year survival rate still as low as 9%1. PDAC is, therefore, projected to be the second cause of 
cancer-related deaths in the USA by  20302 with a similar figure in most Western countries. One of the reasons 
of this meager survival is the lack of specific symptoms and of biological markers for early diagnosis and risk 
stratification. Moreover, treatment options are poor, and surgery in the setting of multimodal treatments is the 
only possible cure. However, there are marked differences in patients’ responses to the treatments, which can-
not be explained by the traditional prognostic factors such as tumour size, lymph node involvement and distal 
 metastasis3. Thus, investigation of biomarkers able to predict the tumour behaviour is of the utmost importance.
Genetic variability accounts for a large part of the risk to develop  PDAC4. Several germline mutations, associ-
ated with well described hereditary syndromes, increase the risk of developing PDAC and subjects carrying such 
mutations are offered surveillance in the context of research  protocols5. Besides these high penetrance germline 
mutations, there are overwhelming evidences on the role of germline genetic polymorphisms in the development 
of the disease, identified through genome-wide association studies (GWAS) or through large scale case–control 
 studies6–21. However, the possible association between genetic variants and patients’ outcome in PDAC, both in 
terms of survival and response to treatments, has been poorly investigated with limited  success22–29. The genetic 
contribution to PDAC survival has, however, been studied with GWAS. For example, a small-scale GWAS done 
on 252 PDAC cases, with subsequent validation done on 261 and 572 sets of patients, respectively, reported an 
association between a single nucleotide polymorphism (SNP) on chromosome 12 and overall survival (OS) of 
PDAC cases (p = 1.72 ×  10−7 in the combined dataset)27. Innocenti et al. reported on a GWAS on OS of 351 pan-
creatic cancer patients treated with gemcitabine in the context of a randomized clinical trial. This study showed 
an association of a SNP in IL17F with OS (p = 9.51 ×  10−7)29. Wu et al. performed the largest GWAS on OS to 
date in 1005 PDAC cases (10), of whom 642 were of European descent (from prospective cohort studies), used 
as discovery phase, and 363 retrospectively collected cases of Chinese descent used for  replication25. In the first 
stage 131 SNPs at 28 loci showed association with OS of the PDAC cases (p <  10−5). Combining the discovery 
and the replication phases, a locus on chromosome 11 near the SBF2 gene was the most significantly associated 
with OS of PDAC patients (p = 1.72 ×  10−7). It is worth noticing that none of the findings of the above mentioned 
GWAS reached genome-wide significance level, conventionally set at p < 5 ×  10−8, and that only a few loci were 
successfully replicated across multiple reports. In one of the few studies of this kind, we genotyped 44 SNPs pro-
posed by the GWAS by Wu et al. in one of the largest study so far consisting in 1722 PDAC cases, in the context 
of the PANDoRA  consortium25. We validated associations of one SNP in the CTNNA2 gene (rs1567532) and one 
SNP in the RUNX2 gene (rs12209785) with  OS26. The lack of replicability of the PDAC survival loci is in striking 
contrast with the situation observed for GWAS-identified risk loci, which are generally confirmed in multiple 
independent studies, to some extent even in populations of diverse ethnic background.
Recently, Dimitrakopoulos and colleagues carried out a genome-wide screening of functional variants aimed 
at identifying novel markers associated with PDAC survival after pancreatic  resection30. The authors used a dense 
SNP array and investigated more than 2 million SNPs in 331 PDAC patients in a two-phase approach. The main 
findings consisted in association of CD44-rs353630 and CHI3L2-rs684559 with PDAC survival. The diplotype 
combination of the two alleles of the two SNPs associated with better survival (C and G, respectively) reached 
genome-wide significance (HR = 0.38, 95%CI 0.27–0.53, p = 1.00 ×  10−8) in the merged population consisting of 
the two phases.
One of the reasons behind the lack of success of studies investigating genetic variants as biomarkers of disease 
outcome is that most studies so far were underpowered and therefore prone to statistical fluctuation, and/or that a 
proper replication phase in an independent adequately sized population was lacking. Considering the capricious 
nature of association studies, we aimed at validating the findings by Dimitrakopoulos and colleagues in a large 
cohort of 1856 PDAC cases among which 685 resected patients with tumour stage I or II from the PANcreatic 
Disease ReseArch (PANDoRA) consortium.
Results
Population description and data filtering. The population investigated in the present study consisted 
overall of 1856 PDAC patients: 105 with stage I, 717 with stage II, 348 with stage III and 686 with stage IV at the 
time of diagnosis. The median age was 66 and both sexes were represented with a slight majority of males (56%). 
685 patients with stage I or II were operated with curative intent. A description of the population is shown in 
Table 1.
The genotyping call rate was 95% for CD44-rs353630 and 96% for CHI3L2-rs684559, the concordance 
between the duplicated samples was higher than 99%. All the SNPs resulted to be in HWE equilibrium with 
non-significant p values (p > 0.05) when considering all the individuals together or dividing them by country 
of origin. The minor frequency (MAF) observed in PANDoRA is 25.62% for CD44-rs353630 and 36.07% for 
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CHI3L2-rs684559, in line with what observed in the European populations in the 1000 Genomes project: 25.35% 
for CD44-rs353630 and 36.88% for CHI3L2-rs684559.
Survival analysis. Analysing the whole PDAC case population and adjusting for age, sex and stage we 
observed no statistically significant association between the two SNPs under investigation and OS of PDAC 
patients, with the best finding consisting in a non-significant trend for the C/C genotype of the CD44-rs353630 
of having a worse survival compared with the T/T homozygous (HR = 1.28, 95% CI 0.98–1.68, p = 0.074). We also 
performed stratified analysis by disease stage and when analysing the individuals that presented stage I disease at 
diagnosis we observed a statistically significant association for the heterozygous C/T carriers of CD44-rs353630 
and worse OS compared with the reference (HR = 5.01; 95% CI 1.58–15.88; p = 0.006). The analysis considering 
only the 685 patients who received surgery did not show any statistically significant associations. We also per-
formed an analysis considering the combination of the two markers and we observed no statistically significant 
result. The frequencies and distribution of the genotypes, the HR and 95% CI for the association with PDAC 
survival are shown in Table 2. A Kaplan–Meier curve with the survival of resected PDAC patients diagnosed in 
stage I or II (p = 0.64), according to the combined genotypes of the two SNPs is showed in Fig. 1. We performed 
additional analyses stratifying by country of origin. We did not observe any statistically significant associations, 
with the exception of a longer OS for patients from Hungary diagnosed with stage I or II PDAC and heterozy-
gous for the CHI3L2-rs684559 SNP, in comparison with the homozygotes for the common allele (HR = 0.19; 95% 
CI 0.05–0.71; p = 0.014).
In silico functional characterization. The GTEx portal identified only one eQTL for CD44-rs353630: 
the weak (p = 0.00025) association between the A allele and a decreased expression of the CD44 gene in the tibial 
nerve. GTEx predicts that CHI3L2-rs684559 is an eQTLs for the CHI3L2, DENND2D, CHIAP2 and CHIA genes 
across seven tissues, although none of them in the pancreas (p-values ranging from 0.000026 to 3.7 ×  10−20). For 
CD44-rs353630 RegulomeDB showed a rank of 4 that is the third lowest and indicates that the polymorphism 
may be situated in a possible transcription factor binding site. On the other hand, for CHI3L2-rs684559 Regu-
lomeDB showed a rank of 1b indicating a very high degree of supporting data in the database and high prob-
ability of functional relevance. Haploreg showed no SNPs in LD with CD44-rs353630 and no eQTLs, while six 
SNPs (rs2764546, rs12048900, rs12024633, rs2494004, rs1325284, rs2494006) in LD with CHI3L2-rs68455 and 
14 eQTLs in lymphoblastoid cell lines and in the whole blood.
Discussion
In the last decades genetic epidemiological approaches, especially those performed through genome-wide asso-
ciation studies in the context of multicentric studies, have identified thousands of SNPs and have shed light on 
the biology of many cancer types. As far as regards PDAC, around 30 risk loci showed a clear association with 
the development of the disease. However, differently from other cancer types such as breast, lung, prostate, 
colorectal cancers, and multiple  myeloma31–37, the involvement of genetic variability in PDAC survival has been 
investigated with limited success. The most reliable factors in determining PDAC patient survival are, therefore, 
clinical parameters such as TNM stage, tumour grade, margins of resection and pre- and postoperative levels of 
C-reactive protein (CRP) and CA-19-938. Unfortunately, these factors have limited accuracy in predicting the 
outcome of PDAC patients and their response to treatments. Therefore, the identification of additional biological 
markers would be of the utmost importance as a basis to elaborate novel decisional algorithms aimed at optimiz-
ing treatment and improving patients’ outcomes. Additionally, discovering new PDAC survival genetic loci may 
give insight to the molecular mechanisms of survival and suggest, directly or indirectly, new therapeutic targets.
Several SNPs have been proposed to be possible prognostic markers in PDAC patients, given the association 
with survival. However, with only a few exceptions, none has been consistently replicated in following  studies25–29. 
Recently two novel candidates, identified through a GWAS approach, have been proposed. A total of 331 PDAC 
patients were investigated by means of a dense SNP array, encompassing more than 2 million SNPs, finding an 
Table 1.  Description of the study population.
Country Patients
Sex (%) Stage Age (years)
Females Males I II III IV Median  (Q1–Q3)
Italy 483 211 272 18 188 86 191 67 (60–74)
Denmark 431 189 242 17 149 64 201 68 (62–73)
Germany 351 136 215 14 244 28 65 65 (58–70)
Hungary 254 130 124 18 16 120 100 65 (59–73)
Czech Republic 151 63 88 27 69 19 36 62 (58–69)
Lithuania 87 41 46 1 21 13 52 69 (60–73)
Poland 46 26 20 8 15 6 17 61 (54–66)
Romania 30 11 19 2 0 10 18 63 (54–67)
The Netherlands 15 6 9 0 10 2 3 68 (60–76)
United Kingdom 8 5 3 0 5 0 3 69 (65–73)
Total 1856 818 1038 105 717 348 686 69 (59–72)
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SNP
All  patientsa All  patientsb Stage  Ic
No. HR (95% CI) p value HR (95% CI) p value No. HR (95% CI) p value
rs353630
T/T 134 1 [Reference] NA 1 [Reference] NA 13 1 [Reference] NA
C/T 683 1.16 (0.94–1.44) 0.165 1.15 (0.93–1.43) 0.206 34 5.01 (1.58–15.88) 0.006
C/C 1039 1.13 (0.92–1.39) 0.259 1.13 (0.91–1.39) 0.258 58 2.20 (0.73–6.61) 0.162
C/T + C/C 1722 1.14 (0.93–1.40) 0.202 1.14 (0.93–1.40) 0.220 92 2.77 (0.95–8.06) 0.062
Resected
T/T 85 1 [Reference] NA 1 [Reference] NA 9 1 [Reference] NA
C/T 372 1.21 (0.92–1.61) 0.178 1.23 (0.93–1.63) 0.152 25 4.43 (0.91–21.64) 0.066
C/C 630 1.26 (0.96–1.65) 0.098 1.28 (0.98–1.68) 0.074 51 2.34 (0.51–10.62) 0.272
C/T + C/C 1002 1.24 (0.95–1.62) 0.111 1.26 (0.97–1.65) 0.087 76 2.70 (0.61–11.91) 0.190
rs684559
A/A 256 1 [Reference] NA 1 [Reference] NA 11 1 [Reference] NA
G/A 827 1.01 (0.86–1.19) 0.918 0.97 (0.82–1.14) 0.719 44 0.50 (0.21–1.20) 0.119
G/G 773 0.96 (0.82–1.13) 0.640 0.94 (0.80–1.11) 0.456 50 0.54 (0.23–1.26) 0.155
G/A + G/G 1600 0.99 (0.85–1.15) 0.849 0.96 (0.82–1.11) 0.558 94 0.52 (0.24–1.16) 0.110
Resected
A/A 157 1 [Reference] NA 1 [Reference] NA 6 1 [Reference] NA
G/A 479 0.99 (0.81–1.24) 0.984 0.97 (0.78–1.20) 0.777 38 0.61 (0.19–1.94) 0.407
G/G 451 1.00 (0.81–1.24) 0.981 0.98 (0.79–1.22) 0.860 41 0.59 (0.19–1.89) 0.376
G/A + G/G 930 1.00 (0.82–1.22) 0.999 0.97 (0.80–1.19) 0.804 79 0.60 (0.20–1.81) 0.367
Combined SNPsd
rs353630 T/T and/or 
rs684559 A/A 368 1 [Reference] NA 1 [Reference] NA 20 1 [Reference] NA
All other genotypes 1488 1.04 (0.91–1.18) 0.582 1.02 (0.89–1.16) 0.826 85 1.38 (0.65–2.91) 0.403
Resected
rs353630 T/T and/or 
rs684559 A/A 229 1 [Reference] NA 1 [Reference] NA 12 1 [Reference] NA
All other genotypes 858 1.06 (0.90–1.27) 0.480 1.06 (0.89–1.26) 0.526 73 1.5 (0.55–4.12) 0.431
SNP
Stage  IIc Stage I and  IIc
No. HR (95% CI) p value No. HR (95% CI) p value
rs353630
T/T 47 1 [Reference] NA 60 1 [Reference] NA
C/T 265 1.08 (0.73–1.59) 0.709 299 1.27 (0.88–1.83) 0.203
C/C 405 1.07 (0.73–1.56) 0.730 463 1.17 (0.82–1.67) 0.388
C/T + C/C 670 1.07 (0.74–1.55) 0.714 762 1.20 (0.85–1.71) 0.295
Resected
T/T 44 1 [Reference] NA 53 1 [Reference] NA
C/T 209 1.08 (0.72–1.62) 0.721 234 1.23 (0.83–1.81) 0.311
C/C 347 1.15 (0.78–1.71) 0.476 398 1.23 (0.84–1.79) 0.291
C/T + C/C 556 1.12 (0.77–1.65) 0.550 685 1.23 (0.85–1.77) 0.282
rs684559
A/A 102 1 [Reference] NA 113
G/A 333 0.93 (0.71–1.22) 0.617 377 0.87 (0.67–1.12) 0.270
G/G 282 0.92 (0.70–1.22) 0.569 332 0.89 (0.68–1.15) 0.364
G/A + G/G 615 0.93 (0.72–1.20) 0.567 709 0.88 (0.69–1.11) 0.278
Resected
A/A 89 1 [Reference] NA 95 1 [Reference] NA
G/A 276 0.89 (0.67–1.19) 0.438 314 0.88 (0.66–1.16) 0.358
G/G 235 0.95 (0.71–1.28) 0.739 276 0.93 (0.70–1.23) 0.606
G/A + G/G 511 0.92 (0.70–1.20) 0.539 590 0.90 (0.69–1.17) 0.432
Combined SNPsd
rs353630 T/T and/or 
rs684559 A/A 144 1 [Reference] NA 164 1 [Reference] NA
All other genotypes 573 0.92 (0.74–1.16) 0.489 658 0.95 (0.77–1.17) 0.623
Resected
rs353630 T/T and/or 
rs684559 A/A 128 1 [Reference] NA 140 1 [Reference] NA
All other genotypes 472 0.93 (0.73–1.19) 0.571 545 0.97 (0.77–1.22) 0.780
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association between CD44-rs353630 and CHI3L2-rs684559 and PDAC survival in resected patients of whom 
90.9% with stage I or II. The diplotype combination of these two alleles was, indeed, associated with longer sur-
vival after  surgery30. We genotyped these two SNPs and analysed them, separately or in combination, in a large 
set of PDAC cases belonging to the PANDoRA consortium. Considering the paucity of evidences on markers 
related to PDAC survival this attempt to generalize the results of the two SNPs was necessary. We had more than 
99% power to replicate the associations, but we observed none when analysing the whole population or when 
considering only the resected patients. The most clinically relevant result of the study by Dimitrakopoulos and 
colleagues is the association of the two combined polymorphisms with better survival in 331 patients resected 
with intent of radicality. Availability of such a biomarker might be extremely relevant as it would help selection 
of patients to consider for upfront surgery or neoadjuvant chemotherapy, thus contributing to a personalized 
medicine approach for PDAC. However, in our subgroup analysis on 685 patients resected with stage I or II 
disease (therefore with a much larger sample size and a power to detect the association greater than 99%) the 
same SNP combination did not show any statistically significant association (the best association we observed 
had a p = 0.48).
Further stratifying the population by stage, we observed a statistically significant association between CD44-
rs353630 C/T individuals and worse OS among PDAC cases diagnosed with stage I. The estimate is very high 
(HR > 5) and it goes in the opposite direction of the ones reported by Dimitrakopoulos, which all showed asso-
ciation of the effect alleles/genotypes with better OS. These findings arise from an analysis conducted in a very 
small subgroup of individuals and only comparing heterozygous with the reference homozygous (N = 34 vs. 13, 
respectively) and therefore must be taken with caution. The analysis conducted to assess the functional relevance 
of the SNPs clearly shows that for CD44-rs353630 there is little or no evidence of its involvement in gene expres-
sion, while CHI3L2-rs684559 is possibly an eQTL with regulatory potential in several tissues, but not in the 
pancreas. It is therefore difficult to link the SNPs to a functional role in pancreatic cancer progression or outcome.
Analyses stratified by country of origin did not show anything remarkable, with the exception of a weak 
association with longer OS in Hungarian patients diagnosed in stage I or II for heterozygous for the CHI3L2-
rs684559 SNP. We note that this association is not significant if we consider a significance threshold adjusted for 
multiple testing (the observed association had p = 0.014, but analyses stratified by 10 countries of origin have an 
adjusted threshold of significance of p = 0.05/10 = 0.005). Considering also the relatively small number of cases 
used for this analysis (18 patients diagnosed with stage I and 16 in stage II), and the difficulty of explaining why 
the polymorphism should be associated with OS only in Hungarian patients, we are inclined to think that this 
result is due to statistical fluctuation and does not reflect a real association. A possible limitation of the present 
study is the lack of information on chemotherapeutic regimens administered to the patients, either before or after 
surgery. This prevents us to explore association between the genetic variability and drug response that may help 
personalization of treatments. In addition, the included patients were not consecutively enrolled in each center, 
and that could add a potential bias to the findings. We believe, however that given the samples size this bias should 
be diluted and unlikely to be responsible for the lack of statistically significant association that we observed.
Material and methods
Study population. The PANDoRA consortium consists of a multicentric study that includes 12 European 
countries (Italy, Germany, Poland, United Kingdom, Hungary, Czech Republic, Greece, Lithuania, the Nether-
lands, Denmark, Ukraine, Romania) and Japan and has been described in detail  elsewhere9.
Briefly, all cases included in the consortium population are defined by a confirmed diagnosis of pancreatic 
cancer and were collected with a non-consecutive sampling approach in 21 different centers, including depart-
ments of surgery, endoscopy and gastroenterology. In addition to pancreatic cancer cases, controls have been 
selected among the general population, blood donors and among hospitalized subjects with different diagnosis 
excluding cancer. In the present study, 1856 PDAC cases of European descent were included, for whom informa-
tion on country of origin, sex, age at diagnosis, overall survival (OS) and disease stage assessed by TNM stage 
was available. Disease stage was defined according to American Joint Committee on Cancer TNM system 7th 
 version39, and patients were categorized as stage I (T1-2, N0, M0), stage II (T3, N0, M0/T1-3, N1, M0), stage 
III (T4, any N, M0), stage IV (any T, any N, M1). The patients that underwent surgery were categorized by the 
stage at the time of operation.
All subjects gave their informed consent for inclusion before they participated in the study. The study was 
conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Com-
mission of the Medical Faculty of the University of Heidelberg (project identification code: S-565/2015). A 
description of the population is shown in Table 1.
SNPs selection, sample preparation and genotyping. We selected two germline variants, CD44-
rs353630 and CHI3L2-rs684559 that were proposed recently by Dimitrakopoulos and colleagues as associated 
with survival of PDAC patients that received surgery. For each subject DNA was extracted from whole blood 
Table 2.  Survival analysis of CD44-rs353630 and CHI3L2-rs684559. NA, not applicable; HR, Hazard Ratio, 
CI, confidence interval. Statistically significant results (p < 0.05) are in bold. Numbers may not add up to the 
total number of subjects in the respective stratum due to missing data. a The analyses were adjusted by tumour 
stage (stages I through IV). b The analyses were adjusted by tumour stage, country of origin, sex and age. c The 
analyses were adjusted by, country of origin, sex and age. d The combined analysys was performed using the 
rs353630 T/T and rs684559 A/A genotypes as reference.
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using a QIAamp 96 DNA QIAcube HT Kit on QIAcube 96 instrument and kept frozen at − 20° till use. Geno-
typing was conducted using TaqMan (ABI, Applied Biosystems, Foster City, CA, USA) allelic discrimination 
technology following the manufacturer’s recommendation (assay id C____779802_10 for CD44-rs353630 and 
assay id C___3138574_20 for CHI3L2-rs684559). For each reaction 10 ng of dried DNA were used. The geno-
typing was conducted in 384-well plates and duplicated samples (8%) were included in each plate for quality 
control purpose. The identity of the samples was not known to the personnel performing the lab work. Genotype 
attribution was made using QuantStudioTM 5 Real-Time PCR system (Thermofisher, USA) and QuantStudio 
software.
Statistical analysis. Deviation from Hardy–Weinberg equilibrium (HWE) was tested for both polymor-
phisms in the overall population and dividing for country of origin using the Pearson corrected chi square test. 
Survival analysis was conducted by Cox proportional hazard models with OS as endpoint, computing hazard 
ratios (HR) and 95% confidence intervals (CI), using an additive and a codominant inheritance models and set-
ting the same alleles used by Dimitrakopoulos and colleagues as the reference category (T for CD44-rs353630 
and A for CHI3L2-rs684559). In addition, considering that the most statistically significant association observed 
by Dimitrakopoulos was the one combining the two genotypes, we also performed this analysis defining two 
groups: the individuals with the CD44-rs353630 T/T and/or CHI3L2-rs684559 A/A as the reference category 
and all the other genotype combinations as the other group. For this analysis we considered only individuals with 
100% call rate. All analyses were adjusted for sex, age and TNM stage. We also performed an analysis adjusting 
only for disease stage, since Dimitrakopoulos and colleagues did not adjust for sex and age.
As the vast majority (90.9%) of the patients in the study by Dimitrakopoulos and colleagues were resected 
with stage I or II, stratified analysis was conducted considering patients showing TNM stage I, TNM stage II, 
and TNM stage I and II together. We also performed a stratified analysis considering TNM stage I and II for 
patients who received surgery, as well as by country of origin. The probability of survival was calculated by means 
of a Kaplan–Meier curve.
Functional analysis using bioinformatic tools. To test the possible functional relevance of CD44-
rs353630 and CHI3L2-rs684559 we used several bioinformatic tools. In particular, the Genotype-Tissue Expres-
sion (GTEx) project portal (https:// gtexp ortal. org/ home/) was used to identify potential cis-acting expression 
quantitative trait loci (eQTLs) in order to establish whether the two SNPs could be involved in the expression of 
nearby genes (accession date 8th May 2020)40. We analysed all the tissues present in the database. We have used 
Regulome DB 2.0 (https:// www. regul omedb. org/ regul ome- search/) to evaluate the effect of the SNPs with regu-
latory regions of the human non-coding  genome41. Regulome DB 2.0 assigns to each SNP a rank consisting of 14 
steps, that reflect the volume of the supporting data on the functional relevance of the SNP, going from 6 (lowest 
amount of evidence) to 1a (highest amount of evidence). Finally, we used Haploreg v4.1 (https:// pubs. broad insti 
tute. org/ mamma ls/ haplo reg/ haplo reg. php) to link the SNPs to functional annotations of the  genome42. Hap-
loreg is designed to explore the possible mechanistic interaction of the candidate SNPs (and all SNPs in LD with 
them) with regulatory motifs.
Figure 1.  Kaplan–Meier curve showing the survival of resected PDAC patients diagnosed in stage I or II, 
according to the combined genotypes of CD44-rs353630 and CHI3L2-rs684559.
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Ethics declarations. The study was conducted in accordance with the Declaration of Helsinki, and the 
protocol was approved by the Ethics Commission of the Medical Faculty of the University of Heidelberg (project 
identification code: S-565/2015).
Conclusions
In conclusion, we attempted to replicate the results of a genome-wide investigation on genetic polymorphisms 
and survival of PDAC patients, with a well-powered study. Our findings suggest no involvement in the PANDoRA 
population of the two variants reported by Dimitrakopoulos and colleagues and highlight a lack of functional or 
regulatory role of CD44-rs353630 and CHI3L2-rs684559 in the pancreatic tissue. Our results strongly support 
the need to consider with caution findings on genetic variables as prognostic markers in PDAC, in the absence of 
replication in large and independent datasets or of compelling in vitro mechanisms to support the associations.
Moreover, it would be desirable for future studies to have information on the therapy and to include this 
information in the analyses. This could make possible to evaluate the different genetic predisposition in drug 
response, and further our knowledge of this deadly disease.
Data availability
Owing to ethical and legal reasons, raw data of this work are not publicly deposited. The PANDoRA primary 
data for this work will be made available to researchers who submit a reasonable request to the corresponding 
author, conditional to approval by the PANDoRA Steering Committee and Ethics Commission of the Medical 
Faculty of the University of Heidelberg. Data will be stripped from all information allowing identification of 
study participants.
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